US Patent No: 8,206,701
Number of patents in Portfolio can not be more than 2000
Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells
Stats
-
Jun 26, 2012
Issued date -
Sep 16, 2003
filing date -
10/665,111
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 4,789,658 Immunoprophylactic and immunotherapeutic agents | 39 | 1986 | |
|
|
|||
| 4,415,553 Compositions, processes for their preparation and method for treatment of neoplasms | 13 | 1980 | |
|
|
|||
| 6,143,292 Allogeneic cell therapy for cancer following allogeneic stem cell transplantation | 8 | 1997 | |
|
|
|||
| 4,568,542 Vaccine compositions | 9 | 1981 | |
|
|
|||
| 6,063,375 Semiallogeneic cell hybrids and related methods for treating cancer | 3 | 1996 | |
|
|
|||
| 6,458,585 Cytokine-free culture of dendritic cells | 8 | 1997 | |
|
|
|||
| 4,877,611 Vaccine containing tumor antigens and adjuvants | 58 | 1987 | |
|
|
|||
| 5,290,551 Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten | 20 | 1992 | |
|
|
|||
| 5,156,841 Anti-tumor vaccine | 8 | 1988 | |
|
|
|||
| 6,077,519 Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients | 14 | 1997 | |
|
|
|||
| 5,582,831 Anti-tumor vaccines | 10 | 1994 | |
|
|
|||
| 2002/0123,479 Immunostimulation mediated by gene-modified dendritic cells | 1 | 2001 | |
| 2002/0168,351 Fusion cells and cytokine compositions for treatment of disease | 2 | 2001 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Dec 26, 2015 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Dec 26, 2019 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Dec 26, 2023 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |